The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Glutaredoxin 1 Downregulation in the Substantia Nigra Leads to Dopaminergic Degeneration in Mice
Abstract
Background: Parkinson's disease (PD) is characterized by a severe loss of the dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Perturbation of protein thiol redox homeostasis has been shown to play a role in the dysregulation of cell death and cell survival signaling pathways in these neurons. Glutaredoxin 1 (Grx1) is a thiol/disulfide oxidoreductase that catalyzes the deglutathionylation of proteins and is important for regulation of cellular protein thiol redox homeostasis. Objectives: We evaluated if the downregulation of Grx1 could lead to dopaminergic degeneration and PD‐relevant motor deficits in mice. Methods: Grx1 was downregulated unilaterally through viral vector‐mediated transduction of short hairpin RNA against Grx1 into the SNpc. Behavioral assessment was performed through rotarod and elevated body swing test. Stereological analysis of tyrosine hydroxylase–positive and Nissl‐positive neurons was carried out to evaluate neurodegeneration. Results: Downregulation of Grx1 resulted in contralateral bias of elevated body swing and reduced latency to fall off, accelerating rotarod. This was accompanied by a loss of tyrosine hydroxylase–positive neurons in the SNpc and their DA projections in the striatum. Furthermore, there was a loss Nissl‐positive neurons in the SNpc, indicating cell death. This was selective to the SNpc neurons because DA neurons in the ventral tegmental area were unaffected akin to that seen in human PD. Furthermore, Grx1 mRNA expression was substantially decreased in the SNpc from PD patients. Conclusions: Our study indicates that Grx1 is critical for the survival of SNpc DA neurons and that it is downregulated in human PD. © 2020 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“suppression of GLRX contributes to PD-relevant motor deficits and dopaminergic degeneration in mice (Verma et al., 2020).”
From Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease (2022) · cites this paper as Verma et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
Zucca, F. A., Segura-Aguilar, J., Ferrari, E., Muñoz, P., Paris, I., Sulzer, D., Sarna, T., Casella, L., & Zecca, L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.09.012 · Cited by 659
Aschauer, D. F., Kreuz, S., & Rumpel, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076310 · Cited by 522
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344
Research works printed but not linked: 49
- 10.1111/j.1471-4159.1990.tb02325.x · DOI · Paper page
- 10.1038/nature05292 · DOI · Paper page
- 10.1016/j.expneurol.2009.03.006 · DOI
- 10.1111/jnc.13731 · DOI
- 10.1007/BF01244786 · DOI
- 10.1007/s00702-012-0905-9 · DOI
- 10.1002/mds.21013 · DOI
- Zheng Q, 2016, Dysregulation of ubiquitin‐proteasome system in neurodegenerative diseases, Front Aging Neurosci, 8
- 10.1002/ana.410320714 · DOI
- 10.1159/000118538 · DOI
- 10.1002/ana.10483 · DOI · Paper page
- 10.1089/ars.2011.4501 · DOI
- Johnson WM, 2015, The roles of redox enzymes in Parkinson's disease: focus on glutaredoxin, Ther Targets Neurol Dis, 2, e790
- 10.1016/j.freeradbiomed.2015.06.041 · DOI
- 10.1096/fj.11-194100 · DOI
- 10.1089/ars.2012.4644 · DOI
- 10.1021/bi00064a021 · DOI
- 10.1093/hmg/ddu542 · DOI
- 10.1089/ars.2009.2832 · DOI
- 10.1007/978-1-60327-295-7_7 · DOI
- 10.1038/mt.2008.73 · DOI
- 10.1016/j.jesp.2013.03.013 · DOI · Paper page
- 10.1523/JNEUROSCI.15-07-05372.1995 · DOI
- 10.1159/000017464 · DOI
- 10.1016/S0301-0082(99)00060-X · DOI · Paper page
- 10.1002/glia.20191 · DOI
- 10.1023/A:1021608724117 · DOI
- 10.1046/j.1471-4159.2002.00990.x · DOI
- 10.1046/j.1471-4159.1999.0721170.x · DOI
- 10.1016/j.bbagen.2012.09.018 · DOI
- 10.1016/S0306-4522(97)00347-3 · DOI
- 10.1523/JNEUROSCI.19-02-00562.1999 · DOI · Paper page
- 10.1038/s41418-018-0229-x · DOI
- 10.1155/2018/4235695 · DOI
- 10.1016/j.redox.2018.11.007 · DOI
- 10.1089/ars.2015.6598 · DOI
- 10.1371/journal.pone.0002459 · DOI
- 10.1096/fj.02-0771fje · DOI
- 10.1016/j.neuint.2007.03.008 · DOI
- 10.1101/cshperspect.a008888 · DOI
- 10.1093/brain/aww080 · DOI
- 10.1093/hmg/ddu542 · DOI
- 10.1096/fj.06-7580com · DOI
- 10.1016/j.freeradbiomed.2014.06.004 · DOI
- 10.3389/fnana.2014.00152 · DOI
- 10.1002/glia.23627 · DOI
- 10.1523/ENEURO.0167-17.2017 · DOI
- 10.1016/0306-4522(93)90175-F · DOI
- 10.1016/0304-3940(82)90390-1 · DOI
Cited by
Sorted by citations
Gong, X., Huang, M., & Chen, L. (2022) · eneuro · doi:10.1523/eneuro.0393-21.2021 · Cited by 55
Metadata
- Authors
- Verma, A., Ray, A., Bapat, D., Diwakar, L., Kommaddi, R. P., Schneider, B. L., Hirsch, E. C., & Ravindranath, V.
- Affiliations
- Centre for Neuroscience Indian Institute of Science Bangalore India
- Brain Mind Institute, Ecole Polytechnique Fédérale de Lausanne, CH‐1015 Lausanne Switzerland
- Institut du Cerveau–ICM Inserm U 1127, CNRS UMR 7225, Sorbonne Université Paris France
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2020-07-03
- Volume
- 35
- Issue
- 10
- Pages
- 1843-1853
- ISSN
- 0885-3185
- 1531-8257
- Cited by
- 12
- References
- 3
- Language
- en
- Funders
- Tata Trusts (JTTO‐001)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review